Off-target binding and poor metabolic stability in adenosine receptor modulation lead to therapeutic failure, which is mitigated through specific triazolopyrimidine and triazolopyrazine scaffold substitutions. These chemical modifications ensure high selectivity for A2A and A2B receptors to improve clinical efficacy.